OBJECTIVES: We reviewed our experience with lung transplant for cystic fibrosis (CF) over a 10-year period to identify factors influencing long-term survival. METHODS: One hundred and twenty-three patients with CF have undergone 131 lung transplant procedures at our institution; 114 have had bilateral sequential lung transplants (DLTX) and nine have had bilateral lower lobe transplants from living donors. Three patients had retransplant for acute graft failure, and five had late retransplant for bronchiolitis obliterans syndrome (BOS). Kaplan-Meier survival was calculated for the entire cohort and for subsets at higher risk of death to determine factors predicting a better outcome. RESULTS: Actuarial survival for the entire group of DLTX CF patients was 81% at 1 year, 59% at 5 years, and 38% at 10 years. Lobar transplant was associated with a poorer survival (37.5% at 1 and 5 years). Among DLTX patients, colonization with Burkholderia cepacia was present in 22 patients and was associated with poorer outcome (1- and 5-year survival 60 and 36% in B. cepacia patients vs. 86 and 64% in non-cepacia patients). DLTX patients younger than age 20 (n=22) had a similar survival to patients age 20 or older (n=90). Being on a ventilator at the time of transplant was not associated with poorer survival (n=8). BOS affects increasing numbers of survivors with time. Five CF patients have been retransplanted due to BOS with one operative death and 1-year survival of 60%. CONCLUSIONS: DLTX has acceptable long term survival in CF adults and children with end stage disease. CF patients colonized with B. cepacia have a worse outcome but transplantation is still warranted.
OBJECTIVES: We reviewed our experience with lung transplant for cystic fibrosis (CF) over a 10-year period to identify factors influencing long-term survival. METHODS: One hundred and twenty-three patients with CF have undergone 131 lung transplant procedures at our institution; 114 have had bilateral sequential lung transplants (DLTX) and nine have had bilateral lower lobe transplants from living donors. Three patients had retransplant for acute graft failure, and five had late retransplant for bronchiolitis obliterans syndrome (BOS). Kaplan-Meier survival was calculated for the entire cohort and for subsets at higher risk of death to determine factors predicting a better outcome. RESULTS: Actuarial survival for the entire group of DLTX CFpatients was 81% at 1 year, 59% at 5 years, and 38% at 10 years. Lobar transplant was associated with a poorer survival (37.5% at 1 and 5 years). Among DLTX patients, colonization with Burkholderia cepacia was present in 22 patients and was associated with poorer outcome (1- and 5-year survival 60 and 36% in B. cepaciapatients vs. 86 and 64% in non-cepacia patients). DLTX patients younger than age 20 (n=22) had a similar survival to patients age 20 or older (n=90). Being on a ventilator at the time of transplant was not associated with poorer survival (n=8). BOS affects increasing numbers of survivors with time. Five CFpatients have been retransplanted due to BOS with one operative death and 1-year survival of 60%. CONCLUSIONS: DLTX has acceptable long term survival in CF adults and children with end stage disease. CFpatients colonized with B. cepacia have a worse outcome but transplantation is still warranted.
Authors: Mohammed Fakhro; Richard Ingemansson; Ingrid Skog; Lars Algotsson; Lennart Hansson; Bansi Koul; Ronny Gustafsson; Per Wierup; Sandra Lindstedt Journal: Interact Cardiovasc Thorac Surg Date: 2016-04-06
Authors: Kaivon Assani; Chandra L Shrestha; Frank Robledo-Avila; Murugesan V Rajaram; Santiago Partida-Sanchez; Larry S Schlesinger; Benjamin T Kopp Journal: J Immunol Date: 2017-01-16 Impact factor: 5.422
Authors: Andrew T Braun; Elliott C Dasenbrook; Ashish S Shah; Jonathan B Orens; Christian A Merlo Journal: J Heart Lung Transplant Date: 2015-06-11 Impact factor: 10.247
Authors: Priscila Dentini; Fernando Augusto Lima Marson; Luciana Cardoso Bonadia; Carmen Sílvia Bertuzzo; Antônio Fernando Ribeiro; Carlos Emílio Levy; José Dirceu Ribeiro Journal: Med Microbiol Immunol Date: 2017-09-30 Impact factor: 3.402
Authors: Elisabeth P Dellon; Mitchell D Shores; Katherine I Nelson; Joanne Wolfe; Terry L Noah; Laura C Hanson Journal: Prog Transplant Date: 2009-12 Impact factor: 1.065